



JC17 Rec'd PCT/PTO

1614  
0350  
07 MAY 2001

PATENT #5

Attorney Docket No.: 6116.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Keith Anderson et al.

Serial No.: 09/757,788

Group Art Unit: To be assigned

Filed: January 10, 2001

Examiner: To be assigned

Confirmation No. 8259

For: Transepithelial Delivery Of GLP-1 Derivatives

RECEIVED

NOV 09 2001

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Box DD  
Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:


1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box DD  
Commissioner for Patents  
Washington, DC 20231

on May 2, 2001.

Sylvia Gonzalez  
(name of person mailing paper)

  
(signature of person mailing paper)



Attorney Docket No.: 6116.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

NOV 09 2001

TECH CENTER 1600/2900

In re Application of: Keith Anderson et al.

Application No.: 09/757,788

Group Art Unit: To be assigned

Filed: January 10, 2001

Examiner: To be assigned

Confirmation No. 8259

For: Transepithelial Delivery Of GLP-1 Derivatives

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed. The references are as follows:

1. Clodfelter DK et al. Pharm Res 15(2) (1998) 254-262
2. Patton JS, Bukar J, Nagarajan. Adv Drug Del Rev 35 (1999) 235-247

3. Evans, WE ed., Applied Pharmacokinetics, 3<sup>rd</sup> ed, Ch1-3, (1992) (Abstract)
4. Schmidt et al (Diabetologia 28) 704-707 (1985)
5. Yu J. Chien YW. Pulmonary Drug delivery Rev Ther Drug sys 14(4) (1997) 395-453)
6. Edwards DA, et al., J Appl Physiol 85(2) (1988) 379-385)
7. EP 0619322
8. EP 0699686
9. EP 0708179
10. US 5,277,195
11. US 5,327,883
12. US 5,492,112
13. US 5,577,497
14. US 5,622,166
15. US 5,645,051
16. US 5,654,007
17. US 5,655,523
18. US 5,694,920
19. US 5,699,649
20. US 5,725,841
21. US 5,780,014
22. US 5,855,913
23. US 5,874,064
24. WO 87/06941
25. WO 90/11296
26. WO 91/11457
27. WO 93/19175
28. WO 93/25579
29. WO 96/32149
30. WO 97/41833
31. WO 97/47286
32. WO 98/08871
33. WO 98/13031
34. WO 98/16205
35. WO 98/25589
36. WO 98/29096
37. WO 98/29098
38. WO 98/29140
39. WO 98/29141
40. WO 98/30262
41. WO 98/34596
42. WO 98/35888
43. WO 98/43658
44. WO 99/16419
45. WO 99/29336
46. WO 99/36334
47. WO 99/43341
48. WO 99/43705


- 49. WO 99/43706
- 50. WO 99/43707
- 51. WO 99/43708
- 52. WO 99/47160
- 53. WO 99/48476

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. 37 C.F.R. § 1.97(b). Therefore, no fee is due.

Respectfully submitted,

Date: 2 May 2001

  
Valeta A. Gregg, Reg. No. 35,127  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



23650

PATENT TRADEMARK OFFICE